Furthermore, we discovered that CCT2 can be encapsulated within exosomes and transferred from breast cancer cells to CD4+ T cells, where it suppresses CD4+ T cell activation by downregulating CD40L expression, thereby promoting tumor immune evasion and progression. Here, CD4 is linked to neoplasm.